期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 154, 期 5, 页码 579-589出版社
WILEY
DOI: 10.1111/j.1365-2141.2011.08786.x
关键词
non-pegylated liposomal doxorubicin; elderly; diffuse large B-cell lymphoma; cardiotoxicity; Charlson Comorbidity Index
类别
资金
- Ministry of Health (Ricerca Corrente and, Ricerca Finalizzata, FSN), Rome, Italy
This Phase II study assessed feasibility and efficacy of a biweekly R-COMP-14 regimen (rituximab, cyclophosphamide, non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone) in untreated elderly patients with poor-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high 'life threat' impact NIA/NCI cardiac comorbidity. A total of 208 courses were delivered, with close cardiac monitoring, to 41 patients (median age: 73 years, range: 62-82; 37% >75 years) at a median interval of 15.6 (range, 13-29) days; 67% completed all six scheduled courses. Response rate was 73%, with 68% complete responses (CR); 4-year disease-free survival (DFS) and time to treatment failure (TTF) were 72% and 49%, respectively. Failures were due to early death (n = 3), therapy discontinuations (no-response n = 2; toxicity n = 6), relapse (n = 6) and death in CR (n = 3). Incidence of cardiac grade 3-5 adverse events was 7/41 (17%; 95% confidence interval: 8-31%). Time to progression and overall survival at 4-years were 77% and 67%, respectively. The Age-adjusted Charlson Comorbidity Index (aaCCI) correlated with failures (P = 0.007) with patients scoring <= 7 having a longer TTF (66% vs. 29%; P = 0.009). R-COMP-14 is feasible and ensures a substantial DES to poor-risk DLBCL patients who would have been denied anthracycline-based treatment due to cardiac morbidity. The aaCCI predicted both treatment discontinuation rate and TTF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据